Compare Abeona Therapeutics Inc (ABEO) vs Applied Digital Corporation (APLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Applied Digital Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Applied Digital Corporation trades at $30.45 (market cap $8.78B). The key difference: Applied Digital Corporation is far larger — about 23.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Applied Digital Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | APLD | |
|---|---|---|
Market Cap | $373.32M | $8.78B |
Sector | Health | Technology |
52-Week High | $7.23 | $49.65 |
52-Week Low | $4.17 | $9.18 |
Enterprise Value | $228.22M | $9.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Applied Digital (APLD) trades at $33.50, up 1.33% with a bearish technical signal despite bullish oscillators. The company shows rapid revenue growth but significant losses, with a -58.38% net margin and negative cash flow from operations. Recent developments include major AI data center expansions and $36 billion in contracted backlog, though profitability remains elusive amid heavy capital spending.
Outlook remains speculative with strong analyst support (100% buy ratings, $71.43 target) but substantial execution risks. The stock offers high-growth AI infrastructure exposure but faces customer concentration, mounting debt, and uncertain path to profitability. Current valuation at 27x sales appears rich given negative earnings and cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Applied Digital Corporation
Applied Digital provides high-performance computing (HPC) infrastructure and cloud services. It designs and operates data centers tailored for AI, machine learning, and other intensive digital workloads across North America.
Read more on APLD →
